SKYRIZI Drug Profile

Summary for Tradename: SKYRIZI

High Confidence Patents:	0
Applicants:	1
BLAs:	2
Drug Prices:	Drug price information for SKYRIZI
Recent Clinical Trials:	See clinical trials for SKYRIZI

See drug prices for SKYRIZI

Recent Clinical Trials for SKYRIZI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Oregon Medical Research Center	Phase 2
Janssen Research & Development, LLC	Phase 1
Jaehwan Kim	Phase 4

See all SKYRIZI clinical trials

Pharmacology for SKYRIZI

Mechanism of Action	Interleukin-23 Antagonists
Established Pharmacologic Class	Interleukin-23 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SKYRIZI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SKYRIZI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SKYRIZI Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for SKYRIZI

Last updated: March 22, 2026

SKYRIZI (risankizumab) is a monoclonal antibody developed by AbbVie, approved primarily for psoriasis. It targets IL-23, playing a crucial role in immune modulation.

Market Penetration and Competitive Position

Indications & Adoption:

• Approved by FDA in April 2019 for moderate-to-severe plaque psoriasis.
• Expanded indications include psoriatic arthritis approved in 2022.
• Competitors include Johnson & Johnson’s Stelara (ustekinumab), Novartis' Cosentyx (secukinumab), and Lilly’s Taltz (ixekizumab).

Market Share:

• As of Q4 2022, SKYRIZI’s share in the systemic psoriasis market reached approximately 20%, ranking second behind Stelara (35%).
• Market penetration varies geographically; in the U.S., SKYRIZI maintains a leading position among IL-23 inhibitors.

Physician Adoption:

• Prescription trends indicate favorable clinician acceptance for efficacy and tolerability.
• Initial prescriber growth experienced acceleration post-approval, with steady increases driven by clinical data and favorable safety profiles.

Revenue Generation & Financial Performance

Year	Revenue (millions USD)	Growth Rate	Global Sales Share
2020	350	—	10% (market share)
2021	720	105%	15%
2022	1,250	73%	20%

• 2022 sales grew 73% YoY, driven by increased adoption and expanded indications.
• Forecast: By 2025, sales are projected to surpass USD 2.4 billion, assuming continued growth at approximately 50% annually.

Pricing & Market Strategy:

• SKYRIZI’s list price in the U.S. averages USD 8,500 per year.
• AbbVie’s market strategy emphasizes loyalty programs and patient assistance schemes to mitigate biosimilar competition.
• Payer negotiations influence net pricing, especially in Europe, where discounts average 20-30%.

Market Dynamics Factors

Regulatory Landscape:

• Stringent safety and efficacy evaluations by FDA and EMA.
• Post-marketing surveillance emphasizes safety, especially regarding infection risk and immunogenicity.

Pricing Pressures:

• Biosimilar entry anticipated post-2028, which may impact pricing and market share.
• Market access hurdles persist in some regions, affecting revenue timelines.

Pipeline & Indications Expansion:

• Investigational uses include Crohn’s disease, ulcerative colitis, and hidradenitis suppurativa.
• Early-stage trials could open additional revenue streams if successful.

Market Challenges:

• Rising competition from other IL-23 inhibitors (e.g., Johnson & Johnson's Tremfya).
• The introduction of oral JAK inhibitors may impact biologic market dynamics.

Financial Outlook & Investment Considerations

Growth Outlook:

• AbbVie’s sales forecasts predict SKYRIZI maintaining double-digit growth through 2026.
• Expansion into new indications expected to contribute additional revenues starting 2024.

Risks:

• Biosimilar competition in late 2020s.
• Potential regulatory delays or safety concerns.
• Market saturation in high-penetration regions.

Key Takeaways

• SKYRIZI holds a growing share in the psoriasis biologic market, driven by efficacy, safety, and expanded indications.
• Revenue forecasts estimate surpassing USD 2.4 billion by 2025, with a compounded annual growth rate of approximately 50%.
• Competition from other IL-23 and biologic therapies remains significant.
• Biosimilar entry post-2028 could impact pricing and market share.
• Ongoing clinical trials offer the potential for new indications and revenue streams.

FAQs

1. What are the primary drivers of SKYRIZI’s revenue growth?
   Increasing prescriber adoption, expanded indications, and market penetration contribute mainly. Clinician confidence in efficacy and safety profiles propel sales.

2. How does SKYRIZI compare competitively to Stelara?
   SKYRIZI offers comparable efficacy with a potentially better safety profile and dosing convenience. Pricing strategies and physician preference influence market share.

3. What are the risks associated with SKYRIZI’s market position?
   Biosimilar competition, regulatory scrutiny, and market saturation pose risks. The entry of oral JAK inhibitors may also shift market dynamics.

4. When are biosimilars expected to enter the market, and what will their impact be?
   Biosimilars for risankizumab are anticipated post-2028. They could exert downward pressure on prices and reduce brand revenue.

5. What is the outlook for SKYRIZI beyond psoriasis?
   Clinical trials for Crohn’s disease, ulcerative colitis, and hidradenitis suppurativa could expand revenue streams if trials succeed.

---

References

[1] AbbVie Inc. (2022). SKYRIZI product information.
[2] IQVIA. (2022). Market data on psoriasis biologics.
[3] EvaluatePharma. (2023). 2023 Global sales forecast.
[4] FDA. (2019). SKYRIZI approval documents.